Table 2.

Crude analysis and adjusted odds ratio for the occurrence of AECOPD according to monocyte percentage.

	Unadjusted Model		Adjusted Logistic Model
	cOR (95% CI)	P-value	aOR (95% CI)	P-value
Monocyte percentage in trisection
Low	2.09 (1.24,3.54)	0.006	1.47 (0.76,2.86)	0.256
Medium	Reference		Reference
High	2.37 (1.41, 3.97)	0.001	2.70 (1.42,5.13)	0.002
Absolute Monocyte Count
Absolute Monocyte count	2.03 (1.23,3.35)	0.006	2.09 (1.16,3.78)	0.014
Absolute Monocyte count in the median
Low (< 0.62)	1		1
High (≥ 0.62)	1.46 (0.98,2.19)	0.066	1.79 (1.08,2.97)	0.024
Absolute Monocyte count in the tertile
Low (< 0.52)	1		1
Medium (0.52 to < 0.76)	1.32 (0.79,2.20)	0.296	2.24 (1.16,4.31)	0.016
High (≥ 0.76)	2.01 (1.22,3.31)	0.006	2.80(1.48,5.29)	0.001

Model adjusted for FEV1, CAT, MMRC, symptom (cough, dyspnea, wheeze), medication use (oral LABA, methylxanthines), comorbidities (HPT, CHF, CPD, sleep disorder, malignancy, Pneumonia), lab data (WBC count, NLR), COPD prescription (COPD triple), these variables were selected from the crude model with p-value < 0.05.

All models have performed the multivariate logistic regression model with a backward eliminating process.